{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:46:12Z","timestamp":1791405972863,"version":"4.3.3"},"reference-count":85,"publisher":"Elsevier BV","issue":"4-5","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.neuropharm.2010.01.005","type":"journal-article","created":{"date-parts":[[2010,1,16]],"date-time":"2010-01-16T09:16:06Z","timestamp":1263633366000},"page":"295-302","source":"Crossref","is-referenced-by-count":43,"title":["Brain lipid metabolism, apolipoprotein E and the pathophysiology of Alzheimer's disease"],"prefix":"10.1016","volume":"59","author":[{"given":"Kelly R.","family":"Bales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2010.01.005_bib1","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1073\/pnas.0812697106","article-title":"Apolipoprotein E \u025b4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia","volume":"106","author":"Agosta","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib2","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1176\/appi.ajp.159.5.738","article-title":"Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies","volume":"159","author":"Alexander","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2010.01.005_bib3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/ng1197-263","article-title":"Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition","volume":"17","author":"Bales","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib4","doi-asserted-by":"crossref","first-page":"15233","DOI":"10.1073\/pnas.96.26.15233","article-title":"Apolipoprotein E is essential for amyloid deposition in the APP (V717F) transgenic mouse model of Alzheimer's disease","volume":"96","author":"Bales","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib5","article-title":"Apolipoprotein E-isoform dependent decrease in brain \u03b2-amyloid following treatment of PDAPP transgenic mice with a LXR agonist","author":"Bales","year":"2008","journal-title":"Soc. Neurosci. Abstr."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib6","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1523\/JNEUROSCI.0887-09.2009","article-title":"Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice","volume":"29","author":"Bales","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0006-8993(99)01894-6","article-title":"Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent","volume":"843","author":"Beffert","year":"1999","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib8","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/0005-2760(94)00232-N","article-title":"Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid","volume":"1255","author":"Borghini","year":"1995","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuropharm.2010.01.005_bib9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/jcbfm.2009.197","article-title":"Altered brain mitochondrial metabolism in healthy aging as assessed by in vivo magnetic resonance spectroscopy","volume":"30","author":"Boumzbeur","year":"2010","journal-title":"J. Cereb. Blood Flow September (Epub ahead of print)"},{"key":"10.1016\/j.neuropharm.2010.01.005_bib10","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1172\/JCI112130","article-title":"Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmylinating glia of the peripheral nervous system","volume":"76","author":"Boyles","year":"1995","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib11","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nrn2620","article-title":"Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy","volume":"10","author":"Bu","year":"2009","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.neuron.2004.09.006","article-title":"Memory and executive function in aging and AD: multiple factors that cause decline and reserve factors that compensate","volume":"44","author":"Buckner","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2010.01.005_bib13","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1001\/archneurol.2008.1","article-title":"Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment","volume":"65","author":"Caselli","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib14","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1176\/appi.ajp.164.6.916","article-title":"Correlations between apolipoprotein E \u025b4 gene dose and whole brain atrophy rates","volume":"164","author":"Chen","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2010.01.005_bib15","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng0694-180","article-title":"Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease","volume":"7","author":"Corder","year":"1994","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/ana.410270502","article-title":"Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity","volume":"27","author":"DeKosky","year":"1990","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib17","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0022-2275(20)32039-3","article-title":"Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin:cholesterol acyltransferease in CSF of normal individuals and patients with Alzheimer's disease","volume":"41","author":"Demeester","year":"2000","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib18","unstructured":"Dennis, N.A., Browndyke, J.N., Stokes, J., Need, A., Burke, J.R., Welsh-Bohmer, K.A., Cabeza, R., 2009. Temporal lobe functional activity and connectivity in young adult APOE \u025b4 carriers. Alzheimer's & Dementia. in press. doi:10.1016\/j\/jalz.2009.07.003."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib19","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1385\/JMN:23:3:255","article-title":"Apolipoprotein E dose-dependent modulation of \u03b2-amyloid deposition in a transgenic mouse model of Alzheimer's disease","volume":"23","author":"DeMattos","year":"2004","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00041433-200104000-00003","article-title":"Cholesterol metabolism in the brain","volume":"12","author":"Dietschy","year":"2001","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1515\/BC.2009.035","article-title":"Central nervous system: cholesterol turnover, brain development and neurodegeneration","volume":"390","author":"Dietschy","year":"2009","journal-title":"Biol. Chem."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/1531-8249(200008)48:2<201::AID-ANA10>3.0.CO;2-X","article-title":"Differences in the A\u03b240\/A\u03b242 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype","volume":"48","author":"Fagan","year":"2000","journal-title":"Ann. Neruol."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib23","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.20730","article-title":"Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A\u03b242 in humans","volume":"59","author":"Fagan","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/biof.37","article-title":"Greasing the wheels of A\u03b2 clearance in Alzheimer's disease: the role of lipids and apolipoprotein E","volume":"35","author":"Fan","year":"2009","journal-title":"BioFactors"},{"key":"10.1016\/j.neuropharm.2010.01.005_bib25","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.278.16.1349","article-title":"Effects of age, sex and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis","volume":"278","author":"Farrer","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.neuropharm.2010.01.005_bib26","doi-asserted-by":"crossref","first-page":"7209","DOI":"10.1073\/pnas.0811879106","article-title":"Distinct patterns of brain activity in young carriers of the APOE \u025b4 allele","volume":"106","author":"Filippini","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib27","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/ana.410380219","article-title":"Apoplipoprotein E episolon 4 and cerebral hemorrhage associated with amyloid angiopathy","volume":"38","author":"Greenberg","year":"1995","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbr.2004.09.019","article-title":"Human apoE targeted replacement mouse lines: h-apoE4 and h-apoE3 mice differ on spatial memory performance and avoidance behavior","volume":"159","author":"Grootendorst","year":"2005","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib29","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2010.01.005_bib30","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2010.01.005_bib31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.neuron.2006.09.016","article-title":"A hundred years of Alzheimer's disease research","volume":"52","author":"Hardy","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2010.01.005_bib32","doi-asserted-by":"crossref","first-page":"12686","DOI":"10.1523\/JNEUROSCI.3189-09.2009","article-title":"Disruption of functional connectivity in clinically normal older adults harboring amyloid burden","volume":"29","author":"Hedden","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib33","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/nrn2009","article-title":"Reelin, lipoprotein receptors and synaptic plasticity","volume":"7","author":"Herz","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib34","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/MOL.0b013e32813aeabf","article-title":"Cholesterol metabolism, apolipoprotein E, adenosine triphosphate-binding cassette transporters, and Alzheimer's disease","volume":"18","author":"Hirsch-Reinshagen","year":"2007","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib35","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1073\/pnas.050004797","article-title":"Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease","volume":"97","author":"Holtzman","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib36","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1073\/pnas.92.8.3586","article-title":"Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome)","volume":"92","author":"Hyman","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib37","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1749-6632.2000.tb06919.x","article-title":"Modulation of A beta deposition in APP transgenic mice by an apolipoprotein E null background","volume":"920","author":"Irizarry","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib38","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.neuroscience.2003.08.007","article-title":"Apolipoprotein E isoform-specific regulation of dendritic spine morphology in apolipoprotein E transgenic mice and Alzheimer's disease patient","volume":"122","author":"Ji","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2010.01.005_bib39","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.neuron.2009.06.026","article-title":"The role of apolipoprotein E in Alzheimer's disease","volume":"63","author":"Kim","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2010.01.005_bib40","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib41","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1161\/ATVBAHA.108.164350","article-title":"Regulation of endogenous apolipoprotein E secretion by macrophages","volume":"28","author":"Kockyx","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib42","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0304-3940(01)02263-7","article-title":"The levels of soluble amyloid beta in different high density lipoprotein subfractions distinguish Alzheimer's and normal aging cerebrospinal fluid: implications for brain cholesterol pathology?","volume":"314","author":"Koudinov","year":"2001","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib43","doi-asserted-by":"crossref","first-page":"501","DOI":"10.7326\/0003-4819-140-7-200404060-00008","article-title":"Survival after initial diagnosis of Alzheimer disease","volume":"140","author":"Larson","year":"2004","journal-title":"Ann. Int. Med."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib44","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1471-4159.2004.02183.x","article-title":"A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion, and cholesterol homeostasis in astrocytes","volume":"88","author":"Liang","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib45","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1126\/science.294.5545.1354","article-title":"CNS synaptogenesis promoted by glia-derived cholesterol","volume":"294","author":"Mauch","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2010.01.005_bib46","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1212\/01.wnl.0000228230.26044.a4","article-title":"[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease","volume":"67","author":"Mintun","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2010.01.005_bib47","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.nbd.2004.11.005","article-title":"Production and characterization of astrocyte-derived human apolipoprotein E\u00a0isoforms from immortalized astrocytes and their interactions with amyloid-\u03b2","volume":"19","author":"Morikawa","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib48","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/archneurol.2009.269","article-title":"APOE predicts A\u03b2 but not Tau Alzheimer's pathology in cognitively normal aging","volume":"66","author":"Morris","year":"2009","journal-title":"Arch. Neurol"},{"key":"10.1016\/j.neuropharm.2010.01.005_bib49","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/hipo.20614","article-title":"Selective effect of age, Apo \u025b4, and Alzheimer's disease on hippocampal subfields","volume":"19","author":"Mueller","year":"2009","journal-title":"Hippocampus"},{"key":"10.1016\/j.neuropharm.2010.01.005_bib50","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1749-6632.1996.tb34431.x","article-title":"Amyloid \u03b2-peptide, APOE genotype and head injury","volume":"777","author":"Nicoll","year":"1996","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib51","first-page":"585","article-title":"Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation","volume":"3","author":"Ohm","year":"1995","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2010.01.005_bib52","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/j.jalz.2007.11.012","article-title":"Apolipoprotein E represents a potent gene-based therapeutic target for the treatment of sporadic Alzheimer's disease","volume":"4","author":"Poirier","year":"2008","journal-title":"Alzhemiers Demen."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib53","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/bies.10195","article-title":"Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes?","volume":"25","author":"Pfrieger","year":"2003","journal-title":"Bioessays"},{"key":"10.1016\/j.neuropharm.2010.01.005_bib54","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1212\/01.WNL.0000128088.08695.05","article-title":"APOE \u025b4 allele is associated with reduced cerebrospinal fluid levels of A\u03b242","volume":"62","author":"Prince","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2010.01.005_bib55","doi-asserted-by":"crossref","first-page":"10658","DOI":"10.1523\/JNEUROSCI.1922-05.2005","article-title":"Effect of domain interaction on apolipoprotein E levels in mouse brain","volume":"25","author":"Ramaswamy","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib56","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJM199603213341202","article-title":"Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele of apolipoprotein E","volume":"334","author":"Reiman","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib57","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1073\/pnas.061509598","article-title":"Declining brain activity in cognitively normal apolipoprotein E \u025b4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease","volume":"98","author":"Reiman","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib58","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1073\/pnas.2635903100","article-title":"Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia","volume":"101","author":"Reiman","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib59","doi-asserted-by":"crossref","first-page":"8299","DOI":"10.1073\/pnas.0500579102","article-title":"Correlations between apolipoprotein E \u025b4 gene dose and brain-imaging measurements of regional hypometabolism","volume":"102","author":"Reiman","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib60","doi-asserted-by":"crossref","first-page":"6820","DOI":"10.1073\/pnas.0900345106","article-title":"Fibrillar amyloid-\u03b2 burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease","volume":"106","author":"Reiman","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib61","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.mcn.2007.01.011","article-title":"The LXR agonist T0901317 selectively lowers hippocampal A\u03b242 and improves memory in the Tg2576 mouse model of Alzheimer's disease","volume":"34","author":"Riddell","year":"2007","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib62","doi-asserted-by":"crossref","first-page":"11445","DOI":"10.1523\/JNEUROSCI.1972-08.2008","article-title":"Impact of apoplipoprotein E (ApoE) polymorphism on brain ApoE levels","volume":"28","author":"Riddell","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib63","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1212\/WNL.43.8.1467","article-title":"Association of apolipoprotein allele \u025b4 with late-onset familial and sporadic Alzheimer's disease","volume":"43","author":"Saunders","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2010.01.005_bib64","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.neurobiolaging.2003.08.002","article-title":"Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies","volume":"24","author":"Scheff","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2010.01.005_bib65","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.neurobiolaging.2005.09.012","article-title":"Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment","volume":"27","author":"Scheff","year":"2006","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2010.01.005_bib66","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/brain\/awp007","article-title":"MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers","volume":"132","author":"Schuff","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2010.01.005_bib67","doi-asserted-by":"crossref","first-page":"9649","DOI":"10.1073\/pnas.90.20.9649","article-title":"Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease","volume":"90","author":"Schmechel","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib68","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1474-4422(05)70248-9","article-title":"Cholesterol in Alzheimer's disease","volume":"4","author":"Shobal","year":"2005","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib69","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1212\/01.wnl.0000311446.61861.e3","article-title":"Whole-brain atrophy rate in Alzheimer disease: identifying fast progressors","volume":"70","author":"Sluimer","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2010.01.005_bib70","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuron.2009.07.003","article-title":"Amyloid deposition is associated with impaired default network function in older persons without dementia","volume":"63","author":"Sperling","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2010.01.005_bib71","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1073\/pnas.90.5.1977","article-title":"Apolipoprotein E: high-avidity binding to \u03b2-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease","volume":"90","author":"Strimatter","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib72","doi-asserted-by":"crossref","first-page":"4725","DOI":"10.1073\/pnas.92.11.4725","article-title":"Apolipoprotein E and Alzheimer disease","volume":"9","author":"Strimatter","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib73","doi-asserted-by":"crossref","first-page":"17972","DOI":"10.1074\/jbc.272.29.17972","article-title":"Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis","volume":"29","author":"Sullivan","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib74","doi-asserted-by":"crossref","unstructured":"Sullivan, P.M., Han, B., Liu, F., Mace, B.E., Ervin, J.F., Wu, S., Koger, D., Paul, S.M., Bales, K.R. Reduced levels of human apoE4 protein in an animal model of cognitive impairment. Neurobiol. Aging, in press. doi:10.1016\/j.neurobiolaging.2009.05.011.","DOI":"10.1016\/j.neurobiolaging.2009.05.011"},{"key":"10.1016\/j.neuropharm.2010.01.005_bib75","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.neuint.2006.05.004","article-title":"Selective loss of proteins in Alzheimer's disease: evidence for an increased severity with APOE \u025b4","volume":"49","author":"Tannenberg","year":"2006","journal-title":"Neurochemistry"},{"key":"10.1016\/j.neuropharm.2010.01.005_bib76","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/S0140-6736(97)04318-3","article-title":"Association of apolipoprotein E polymorphism with outcome after head injury","volume":"350","author":"Teasdale","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2010.01.005_bib77","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1097\/00001756-200412030-00020","article-title":"ApoE isoform affects LTP in human targeted replacement mice","volume":"15","author":"Trommer","year":"2004","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2010.01.005_bib78","first-page":"671","article-title":"Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease","volume":"118","author":"Wahrle","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib79","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s004010051190","article-title":"Apolipoprotein E4 promotes the early deposition of A\u03b242 and then A\u03b240 in the elderly","volume":"100","author":"Walker","year":"2000","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib80","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.nbd.2004.10.013","article-title":"Human apoE4-targeted replacement mice display synaptic deficits in the absence of neuropathology","volume":"18","author":"Wang","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib81","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0065-3233(08)60642-7","article-title":"Apolipoprotein E: structure\u2013function relationships","volume":"45","author":"Weisgraber","year":"1994","journal-title":"Adv. Protein Chem."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib82","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1212\/01.wnl.0000238079.00472.3a","article-title":"Regional brain atrophy in cognitively intact adults with a single APOE \u025b4 allele","volume":"67","author":"Wishart","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2010.01.005_bib83","first-page":"31770","article-title":"Isolation and characterization of apolipoproteins from murine microglia","volume":"275","author":"Xu","year":"2000","journal-title":"J. Biochem."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib84","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.mcn.2007.06.009","article-title":"A SAGE study of apolipoprotein E3\/3, E3\/4, and E4\/4 allele-specific gene expression in hippocampus of Alzheimer disease","volume":"36","author":"Xu","year":"2007","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2010.01.005_bib85","doi-asserted-by":"crossref","first-page":"27273","DOI":"10.1074\/jbc.M109.014464","article-title":"Apolipoprotein E4 domain interaction induces endoplasmic reticulum stress and impairs astrocyte function","volume":"284","author":"Zhong","year":"2009","journal-title":"J. Biol. Chem."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390810000079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390810000079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T11:36:51Z","timestamp":1634729811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390810000079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":85,"journal-issue":{"issue":"4-5","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0028390810000079"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2010.01.005","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}